A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015

The American Cancer Society has challenged the U.S. to reduce cancer mortality rates 50% over the 25 years from 1990 to 2015. The current report is an analysis and commentary on progress toward that goal through 2002, the midpoint of the challenge period.

[1]  Pamela A. Shaw,et al.  Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. , 2002, Urology.

[2]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.

[3]  P. Klein,et al.  Targeted therapy: wave of the future. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. V. von Eschenbach,et al.  NCI sets goal of eliminating suffering and death due to cancer by 2015. , 2003, Journal of the National Medical Association.

[5]  Harry J de Koning,et al.  Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial , 2002, International journal of cancer.

[6]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[7]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[8]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[9]  R. Stafford,et al.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence. , 2004, JAMA.

[10]  Michael M Lieber,et al.  Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2005, Journal of the National Cancer Institute.

[11]  Nea Malila,et al.  Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. , 2003, JAMA.

[12]  B. Turnbull,et al.  Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial , 2003, BJU international.

[13]  J. Crowley,et al.  Estimated impact of the Prostate Cancer Prevention Trial on population mortality , 2005, Cancer.

[14]  Ahmedin Jemal,et al.  Cancer Disparities by Race/Ethnicity and Socioeconomic Status , 2004, CA: a cancer journal for clinicians.

[15]  J. Couzin Halt of Celebrex Study Threatens Drug's Future, Other Trials , 2004, Science.

[16]  D. Makuc,et al.  Health, United States, 2003; with chartbook on trends in the health of Americans , 2003 .

[17]  H M Rosenberg,et al.  Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. , 2001, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[18]  J. R. Scotti,et al.  Available From , 1973 .

[19]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[20]  D. Miglioretti,et al.  Hormone Therapy Prescribing Patterns in the United States , 2004, Obstetrics and gynecology.

[21]  ROBERT W. Johnson,et al.  Healthy people. , 1985, Canadian journal of public health = Revue canadienne de sante publique.

[22]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  Susan J. Curry,et al.  Fulfilling the Potential of Cancer Prevention and Early Detection , 2003 .

[24]  A. Zauber,et al.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. , 1993 .

[25]  A. Jerant,et al.  Age-Related Disparities in Cancer Screening: Analysis of 2001 Behavioral Risk Factor Surveillance System Data , 2004, The Annals of Family Medicine.

[26]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[27]  T. Allen-Mersh,et al.  Cancer Control Objectives for the Nation: 1985–2000: NCI Monographs No. 2 , 1987 .

[28]  David C. Smith,et al.  Advances in Prostate Cancer Chemotherapy: A New Era Begins 1 , 2005, CA: a cancer journal for clinicians.

[29]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[30]  Stella M. Yu Healthy People 2010 , 1998, Maternal and Child Health Journal.

[31]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[32]  D. Wickerham Tamoxifen versus raloxifene in the prevention of breast cancer. , 2002, European journal of cancer.

[33]  T. Byers,et al.  The American Cancer Society challenge goals , 1999, Cancer.

[34]  M. Thun,et al.  Aspirin use and reduced risk of gastrointestinal tract cancers in the American Cancer Society prospective studies. , 1995, Preventive medicine.

[35]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. , 1999, Journal of the National Cancer Institute.

[36]  John A. H. Lee Health: United States , 1986 .

[37]  D. Jäger,et al.  [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[38]  A. DeMichele,et al.  Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma , 2003, Cancer.

[39]  F Vinicor,et al.  The continuing epidemics of obesity and diabetes in the United States. , 2001, JAMA.

[40]  M. Cowen,et al.  The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. , 2003, Archives of internal medicine.

[41]  R. Stafford,et al.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence. , 2004, JAMA.

[42]  S. L. Murphy,et al.  Deaths: final data for 2002. , 2004, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[43]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[44]  Ruth Etzioni,et al.  Estimated impact of the prostate cancer prevention trial on population mortality , 2005, Cancer.

[45]  James L Mulshine,et al.  Lung cancer screening with spiral CT: toward a working strategy. , 2004, Oncology.

[46]  E. Feuer,et al.  Impact of screening on incidence and mortality of prostate cancer in the United States. , 2001, Epidemiologic reviews.

[47]  Karla Kerlikowske,et al.  Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results , 2004, Annals of Internal Medicine.